VST Centre for Glaucoma, L.V Prasad Eye Institute, Hyderabad, India.
Centre for Sight, Banjara Hills, Hyderabad, India.
Indian J Ophthalmol. 2018 Sep;66(9):1278-1283. doi: 10.4103/ijo.IJO_195_18.
The purpose of the study is to report the outcomes of simultaneous cataract extraction (CE) and a new nonvalved glaucoma drainage device (GDD), Aurolab Aqueous Drainage Implant (AADI), in eyes with cataract and refractory glaucoma.
This was a non-comparative, interventional, retrospective study. Consecutive patients who underwent AADI together with phacoemulsification from June-2015 to January-2017 by a single fellowship trained glaucoma surgeon with documented 3-months of follow-up were included. The main outcomes were intraocular pressure (IOP), antiglaucoma medication (AGM), visual acuity, and complications.
We included 19 eyes of 17 patients with average follow-up of 14.4 ± 8.4 months. IOP and AGM reduced from 36.9 ± 11.1 mmHg and 4 ± 0.8 preoperatively to 12 ± 4.5 mmHg and 0.8 ± 1.2, respectively (P < 0.001). Complications were seen in seven eyes (36.8%). Total success was seen in 17 eyes (89.5%). None of the patients lost vision.
Combining cataract extraction with the new non-valved Aurolab Aqueous Drainage Implant, appears to be an effective and safe technique in eyes with refractory glaucoma and cataract. Larger studies and further follow-up is recommended for such patients.
本研究旨在报告同时进行白内障摘除术(CE)和新型无阀青光眼引流装置(GDD)、奥罗拉水引流植入物(AADI)治疗白内障合并难治性青光眼患者的结果。
这是一项非对照、干预性、回顾性研究。纳入 2015 年 6 月至 2017 年 1 月期间由一位接受过青光眼专科医师培训的研究员施行白内障超声乳化术联合 AADI 的连续患者,随访时间不少于 3 个月。主要观察指标包括眼压(IOP)、抗青光眼药物(AGM)、视力和并发症。
共纳入 17 例患者的 19 只眼,平均随访时间为 14.4 ± 8.4 个月。IOP 和 AGM 分别从术前的 36.9 ± 11.1mmHg 和 4 ± 0.8 降至术后的 12 ± 4.5mmHg 和 0.8 ± 1.2(P<0.001)。7 只眼(36.8%)出现并发症。17 只眼(89.5%)达到完全成功。无患者视力丧失。
白内障摘除术联合新型无阀奥罗拉水引流植入物治疗白内障合并难治性青光眼,似乎是一种有效且安全的技术。建议对这类患者进行更大规模的研究和进一步随访。